USA — A new study published in the New England Journal of Medicine has found promising results for a weight-loss drug in the U.S.<br /><br />Researchers say lorcaserin, also known under the trade name of Belviq in the U.S., [c][d]is the first drug for weight-loss that does not increase the risk of heart issues.<br /><br />Half of the 12,000 participants in the study were given lorcaserin, which is designed to suppress appetite, while the other half were given a placebo.<br /><br />The drug is supposed to be taken twice a day and will would stimulate brain chemicals to bring about a feeling of fullness.<br /><br />However, the researchers noted that side effects such as headaches and nausea may also be caused by the drug.<br /><br />After 40 months, the study found that the participants prescribed lorcaserin were three times more likely to lose 5 to 10 percent of their body weight compared to those taking a placebo. <br /><br />However, according an editorial published in the New England Journal of Medicine, patients are advised to use the drugs on a "cautious basis" based on their needs.
